Frequency Therapeutics Sponsored Trial First in Human Safety Study of FX-345 in Adults With Sensorineural Hearing Loss Posted to Clinical Trials Website; Study is Now Recruting
https://clinicaltrials.gov/ct2/show/NCT05664100
Why Tupperware Brands Shares Dipped Around 42%; Here Are 89 Biggest Movers From Yesterday
Gainers
Starry Group Holdings, Inc. (NYSE: STRY) rose 55.6% to close at $0.28 on Wednesday after reporting Q3 results.
Baird Initiates Coverage On Frequency Therapeutics with Outperform Rating, Announces Price Target of $10
Baird analyst Jack Allen initiates coverage on Frequency Therapeutics (NASDAQ:FREQ) with a Outperform rating and announces Price Target of $10.
Frequency Therapeutics Completes Enrollment Of Phase 2b Study Of FX-322 For The Treatment Of Sensorineural Hearing Loss
Frequency Therapeutics, Inc. (NASDAQ:FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person's innate potential to restore function, today announced that it has
Tesla, Twitter And 76 Biggest Movers From Friday
Gainers
Seritage Growth Properties (NYSE: SRG) shares surged 80.3% to settle at $10.96 after the company appointed Adam Metz as Chairman. Preliminary proxy materials also indicated the board recommended shareholders to approve a proposed plan sale.
Tesla, WD-40 Company And 40 Stocks Moving In Friday’s Mid-Day Session
Gainers
Aditxt, Inc. (NASDAQ: ADTX) shares surged 75.7% to $0.2812 after the company's Adimune therapeutic program completed a toxicology study indicating a favorable safety profile of ADI-100.
Frequency Therapeutics Q1 EPS $(0.67) Down From $(0.60) YoY
Frequency Therapeutics (NASDAQ:FREQ) reported quarterly losses of $(0.67) per share. This is a 11.67 percent decrease over losses of $(0.60) per share from the same period last year.
Stocks That Hit 52-Week Lows On Friday
During Friday's morning session, 234 stocks hit new 52-week lows.
B. Riley Securities Maintains Buy on Frequency Therapeutics, Lowers Price Target to $10
B. Riley Securities analyst Mayank Mamtani maintains Frequency Therapeutics (NASDAQ:FREQ) with a Buy and lowers the price target from $17 to $10.